ArticleInternational journal of biological sciences2026
Intestine-specific Faf2 depletion ameliorates obesity and metabolic dysfunction-associated steatotic liver disease by impairing lipid absorption.
Article in International journal of biological sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fas-associated factor family member 2 (Faf2) is an endoplasmic reticulum (ER)-associated protein implicated in apolipoprotein B (ApoB) metabolism, yet its physiological role in the intestine remains unclear. To investigate this, we generated intestine-specific Faf2 knockout (Faf2-IKO) mice and fed them either a normal diet or a high-fat diet (HFD). Faf2-IKO mice exhibited reduced body weight and adiposity under both conditions, improved glucose tolerance, and protection against HFD-induced hepatic steatosis. In the intestine, Faf2 deficiency was associated with lipid droplet accumulation, intracellular retention of ApoB48, and reduced chylomicron abundance in lacteals, consistent with impaired intestinal lipoprotein handling. Faf2-IKO mice also exhibited elongation of the small intestine and villi after weaning. Despite these changes, Faf2-IKO mice showed elevated postprandial triglyceride and free fatty acid levels during lipid tolerance tests, indicating paradoxical alterations in postprandial lipid responses. Additionally, Faf2 deficiency was associated with ER dilation and increased expression of genes associated with ER-related cellular responses. Furthermore, in the livers of Faf2-IKO mice, genes that govern cholesterol homeostasis and sterol biosynthetic pathways were significantly enriched. Collectively, these findings suggest that intestinal Faf2 deficiency alters chylomicron-associated lipid handling and is associated with protection against obesity and metabolic dysfunction-associated steatotic liver disease in mice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.